Document is current

Article History

Received: 3 April 2022

Accepted: 24 June 2022

First Online: 29 September 2022

Declarations

:

: Financial interests: Kosuke Kawaguchi has received research support from Eli Lily and Kyoto BC Research Network (KBCRN). Kosuke Kawaguchi received a speaking fee from Chugai Pharmaceutical and Eisai. Masakazu Toi has received research support from Chugai, Takeda, Pfizer, Kyowa-Kirin, Taiho, JBCRG assoc., Eisai, Eli Lilly, Daiichi-Sankyo, AstraZeneca, Astellas, Shimadzu, Yakult, Nippon Kayaku, AFI technology, Luxonus, and Shionogi. Masakazu Toi received a speaking fee from Chugai, Takeda, Pfizer, Kyowa-Kirin, Taiho, Eisai, Daiichi-Sankyo, AstraZeneca, Eli Lilly, MSD, Exact Science, Novartis, Konica Minolta, Shimadzu, Yakult, and Nippon Kayaku. Non-financial interests: Masakazu Toi is on the Board of Director of the JBCRG, OOTR, and KBCRN. Masakazu Toi is on the Advisory Board of the Kyowa-Kirin, Daiichi-Sankyo, Eli Lilly, Konica Minolta, BMS, and Athenex Oncology. Yurina Maeshima has no COI.

: Not applicable.

: Not applicable.

: Not applicable.